Clinical trials: Relapse Schizophrenia
Schizophrenia, Schizoaffective Disorder
Prediction of Relapse in Schizophrenia/Schizoaffective Disorder With Smartphones and On-body Sensors
This study is dedicated to achieving a better understanding of how to identify patterns that indicate someone might be at high risk for relapse in schizophrenia or schizoaffective disorder.
- Trial name
- NCT02224430
- Testing
- schizophrenia/schizoaffective disorder.
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Alabama at Birmingham
Patients Diagnosed With Severe Mental Illness
From Compliance to Alliance: Engaging Psychiatric Patients in Illness Management
The purpose of this study is to determine the benefit and impact on relapse prevention,adherence to treatment and general health indices of participation in psycho-eduational group intervention among psychiatric patients with…
- Trial name
- NCT00192751
- Testing
- Psychoeducational group sessions
- Where
- Israel
- Volunteers
- 150 people
- Sponsor
- Rambam Health Care Campus
Psychosis
Predicting Psychotic Relapse Using Speech-Based Early Detection
Psychotic disorders, including schizophrenia and affective psychosis, are severe mental health conditions marked by recurrent episodes that contribute to long-term disability.
- Trial name
- MOTS+ (NCT06978894)
- Where
- 3 sites in Canada
- Volunteers
- 250 people
- Sponsor
- Douglas Mental Health University Institute
Schizophrenia Relapse, Light Pollution
Indoor Artificial Light at Night and the Relapse Risk of Schizophrenia
A randomized crossover trial of ALAN intervention was conducted in patients with chronic schizophrenia in Anhui Mental Health Center from August 15 to September 30, 2022.
- Trial name
- NCT05986409
- Testing
- light cover
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Weizhuo Yi
Nicotine Dependence, Schizophrenia
Extended Duration Nicotine Replacement Therapy and Bupropion in Smokers With Schizophrenia
After successfully quitting smoking, smokers with schizophrenia are vulnerable to relapse shortly after discontinuation of treatment.
- Trial name
- NCT01576640
- Testing
- NRT, Bupropion SR 150mg bid, Relapse Prevention-Oriented Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital
Mania (Neurotic)
A Probiotic Intervention to Prevent Relapse Following Hospitalization for Mania
This will be a 24-week, randomized, double-blind, placebo-controlled trial of adjunctive probiotic therapy in 66 persons hospitalized with a manic or mixed episode.
- Trial name
- NCT03383874
- Testing
- Probio-Tec BG-VCap-6.5
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of Texas Southwestern Medical Center
Schizophrenia
Antipsychotic Therapy and First Episode
For schizophrenic patients who remained in remission while on maintenance medication, there may come a point in time when the relative risk for relapse become so low that discontinuation of therapy can be considered.
- Trial name
- NCT00334035
- Testing
- Quetiapine
- Where
- Hong Kong
- Volunteers
- 169 people
- Sponsor
- The University of Hong Kong
Schizophrenia
An Efficacy Study of Paliperidone for the Prevention of Relapse in Participants With Schizophrenia
The purpose of this study is to evaluate the efficacy, tolerability and safety of paliperidone extended release (ER) tablets (between 3 to 12 milligram (mg), once a day) in the prevention of relapse in schizophrenia participants.
- Trial name
- NCT01662310
- Testing
- Paliperidone
- Where
- 14 sites in China
- Volunteers
- 201 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia, Schizoaffective Disorder
A New Paradigm for Illness Monitoring and Relapse Prevention in Schizophrenia
This study was a 2-arm randomized control trial (RCT) designed to test a multi-modal smartphone data collection system that provided mobile monitoring of schizophrenia to detect early signs of relapse.
- Trial name
- NCT01952041
- Testing
- Device: Smartphone, Treatment as usual
- Where
- United States
- Volunteers
- 149 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia
Mozart Relapse Study
To assess the long-term efficacy of oral Ziprasidone in the maintenance treatment of resistant schizophrenic subjects who have benefited from participation in the phase III ziprasidone study A1281039 (MOZART study), to assess the…
- Trial name
- NCT00143351
- Testing
- Ziprasidone
- Where
- 16 sites in Italy
- Volunteers
- 75 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Schizoaffective Disorder, Depressive Type
Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
This 12-month study will evaluate the efficacy of aripiprazole lauroxil compared to oral aripiprazole in preventing the re-emergence of psychotic symptoms in patients with a recent onset of schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Depressive Type, Schizophreniform Disorder
- Trial name
- APPRAISE (NCT04203056)
- Testing
- Aripiprazole Lauroxil, ARI-ORAL, AL-NCD
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, Los Angeles
Schizophrenia
A 20-Year Follow-up of First Episode Psychosis: Longitudinal Effects of Early Treatment Strategies and Relapse
The study aims to address the following questions: 1. Do subgroups defined by early medication choices, relapse, and medication taken over 20 years differ in clinical, cognitive, and functional outcomes? 2.
- Trial name
- NCT07616999
- Where
- China
- Volunteers
- 178 people
- Sponsor
- The University of Hong Kong
Schizophrenia, Schizoaffective Disorder
A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder
The purpose of the study is to compare the time to relapse in patients with schizophrenia and schizoaffective disorders receiving risperidone or haloperidol (antipsychotic medications) for at least 1 year.
- Trial name
- NCT00253110
- Testing
- risperidone, haloperidol
- Volunteers
- 396 people
- Sponsor
- Janssen, LP
Schizophrenia
28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years
The study will assess the use of paliperidone palmitate compared with oral risperidone in delaying time to relapse in patients recently diagnosed with schizophrenia who are at high risk of relapse.
- Trial name
- NCT00946985
- Testing
- paliperidone palmitate, oral risperidone
- Where
- 72 sites in United States, Brazil and 10 more
- Volunteers
- 163 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Relapse in Schizophrenia
Seroquel XR in the Long Term Treatment of Schizophrenia
The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improves the relapse prevention in schizophrenic outpatients
- Trial name
- SereNIS (NCT01202617)
- Where
- 61 sites in Hungary
- Volunteers
- 1,606 people
- Sponsor
- AstraZeneca
Patients With Schizophrenia
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia
Schizophrenia is a severe chronic mental disorder with a long-term treatment. Most antipsychotic (AP) drugs are effective for only 30% to 60% of patients and for many drugs, treatment selection remains a "trial-and-error"…
- Trial name
- PROMISE (NCT05839613)
- Testing
- Therapeutic Drug Monitoring (TDM) and Pharmacogenetics (PG)
- Volunteers
- 400 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Schizophrenia
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia
- Trial name
- NCT07686263
- Testing
- Xanomeline/Trospium Chloride
- Where
- 59 sites in United States, Argentina and 7 more
- Volunteers
- 472 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Schizophrenia, Schizoaffective Disorder
Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy
This study is designed to find out whether taking antipsychotic medication once every two weeks by injection compared to taking daily oral medication will help people with schizophrenia maintain better control of their symptoms.
- Trial name
- PROACTIVE (NCT00330863)
- Testing
- Risperidone microspheres, Risperidone, Olanzapine
- Where
- 8 sites in United States
- Volunteers
- 357 people
- Sponsor
- Northwell Health
Schizophrenia, Schizoaffective Disorder
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Varenicline (Chantix) is a smoking cessation treatment that was approved in 2006 by the FDA for treatment of nicotine dependence and may be particularly beneficial in smokers with schizophrenia or bipolar disorder.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Smoking
- Trial name
- SCRP (NCT00621777)
- Testing
- Varenicline
- Where
- 10 sites in United States
- Volunteers
- 247 people
- Sponsor
- Massachusetts General Hospital
Bipolar Disorder, Schizoaffective Disorder
Probiotics to Prevent Relapse After Hospitalization for Mania
The purpose of this study is to determine if taking a probiotic supplement versus a placebo will lower rates of relapse and improve the clinical course among participants who have been hospitalized for mania.
- Trial name
- NCT01731171
- Testing
- Probiotic Supplement, Inert Compound
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Sheppard Pratt Health System